-
Something wrong with this record ?
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity
T. Spelman, D. Horakova, S. Ozakbas, R. Alroughani, M. Onofrj, T. Kalincik, A. Prat, M. Terzi, P. Grammond, F. Patti, T. Csepany, C. Boz, J. Lechner-Scott, F. Granella, F. Grand'Maison, A. van der Walt, C. Zhu, H. Butzkueven, MSBase Study Group
Language English Country Netherlands
Document type Journal Article
- MeSH
- Adult MeSH
- Fingolimod Hydrochloride MeSH
- Immunologic Factors MeSH
- Immunosuppressive Agents MeSH
- Humans MeSH
- Natalizumab MeSH
- Recurrence MeSH
- Multiple Sclerosis, Relapsing-Remitting * MeSH
- Multiple Sclerosis * MeSH
- Comparative Effectiveness Research MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Patients with relapsing-remitting multiple sclerosis (RRMS) who experience relapses on a first-line therapy (interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide; collectively, "BRACETD") often switch to another therapy, including natalizumab or fingolimod. Here we compare the effectiveness of switching from a first-line therapy to natalizumab or fingolimod after ≥1 relapse. METHODS: Data collected prospectively in the MSBase Registry, a global, longitudinal, observational registry, were extracted on February 6, 2018. Included patients were adults with RRMS with ≥1 relapse on BRACETD therapy in the year before switching to natalizumab or fingolimod. Included patients received natalizumab or fingolimod for ≥3 months after the switch. RESULTS: Following 1:1 propensity score matching, 1000 natalizumab patients were matched to 1000 fingolimod patients. Mean (standard deviation) follow-up time was 3.02 (2.06) years after switching to natalizumab and 2.58 (1.64) years after switching to fingolimod. Natalizumab recipients had significantly lower annualized relapse rate (relative risk=0.66; 95% confidence interval [CI], 0.59-0.74), lower risk of first relapse (hazard ratio [HR]=0.69; 95% CI, 0.60-0.80), and higher confirmed disability improvement (HR=1.27; 95% CI, 1.03-1.57) than fingolimod recipients. No difference in confirmed disability worsening was observed. CONCLUSIONS: Patients with RRMS switching from BRACETD demonstrated better outcomes with natalizumab than with fingolimod.
CISSS de Chaudière Appalaches Lévis QC Canada
Department of Neurology Faculty of Medicine University of Debrecen Debrecen Hungary
Department of Neurology Monash University Melbourne VIC Australia
Department of Neuroscience Imaging and Clinical Sciences University G d'Annunzio Chieti Italy
Division of Neurology Department of Medicine Amiri Hospital Sharq Kuwait
Dokuz Eylul University Konak Izmir Turkey
Hôpital Notre Dame Montreal QC Canada and CHUM and Université de Montréal Montreal QC Canada
KTU Medical Faculty Farabi Hospital Trabzon Turkey
Medical Faculty 19 Mayis University Samsun Turkey
Neurosciences Unit Department of Medicine and Surgery University of Parma Parma Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004284
- 003
- CZ-PrNML
- 005
- 20230425141248.0
- 007
- ta
- 008
- 230418s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.msard.2022.104477 $2 doi
- 035 __
- $a (PubMed)36746088
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Spelman, Tim $u Central Clinical School, Monash University, Melbourne, VIC, Australia, and Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. Electronic address: tim@burnet.edu.au
- 245 10
- $a Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity / $c T. Spelman, D. Horakova, S. Ozakbas, R. Alroughani, M. Onofrj, T. Kalincik, A. Prat, M. Terzi, P. Grammond, F. Patti, T. Csepany, C. Boz, J. Lechner-Scott, F. Granella, F. Grand'Maison, A. van der Walt, C. Zhu, H. Butzkueven, MSBase Study Group
- 520 9_
- $a BACKGROUND: Patients with relapsing-remitting multiple sclerosis (RRMS) who experience relapses on a first-line therapy (interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide; collectively, "BRACETD") often switch to another therapy, including natalizumab or fingolimod. Here we compare the effectiveness of switching from a first-line therapy to natalizumab or fingolimod after ≥1 relapse. METHODS: Data collected prospectively in the MSBase Registry, a global, longitudinal, observational registry, were extracted on February 6, 2018. Included patients were adults with RRMS with ≥1 relapse on BRACETD therapy in the year before switching to natalizumab or fingolimod. Included patients received natalizumab or fingolimod for ≥3 months after the switch. RESULTS: Following 1:1 propensity score matching, 1000 natalizumab patients were matched to 1000 fingolimod patients. Mean (standard deviation) follow-up time was 3.02 (2.06) years after switching to natalizumab and 2.58 (1.64) years after switching to fingolimod. Natalizumab recipients had significantly lower annualized relapse rate (relative risk=0.66; 95% confidence interval [CI], 0.59-0.74), lower risk of first relapse (hazard ratio [HR]=0.69; 95% CI, 0.60-0.80), and higher confirmed disability improvement (HR=1.27; 95% CI, 1.03-1.57) than fingolimod recipients. No difference in confirmed disability worsening was observed. CONCLUSIONS: Patients with RRMS switching from BRACETD demonstrated better outcomes with natalizumab than with fingolimod.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a fingolimod hydrochlorid $7 D000068876
- 650 _2
- $a imunologické faktory $7 D007155
- 650 _2
- $a imunosupresiva $7 D007166
- 650 12
- $a roztroušená skleróza $7 D009103
- 650 12
- $a relabující-remitující roztroušená skleróza $7 D020529
- 650 _2
- $a natalizumab $7 D000069442
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a srovnávací výzkum účinnosti $7 D057186
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Ozakbas, Serkan $u Dokuz Eylul University, Konak, Izmir, Turkey
- 700 1_
- $a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait
- 700 1_
- $a Onofrj, Marco $u Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy
- 700 1_
- $a Kalincik, Tomas $u CORe, Department of Medicine, University of Melbourne, and Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia
- 700 1_
- $a Prat, Alexandre $u Hôpital Notre Dame, Montreal, QC, Canada, and CHUM and Université de Montréal, Montreal, QC, Canada
- 700 1_
- $a Terzi, Murat $u Medical Faculty, 19 Mayis University, Samsun, Turkey
- 700 1_
- $a Grammond, Pierre $u CISSS de Chaudière-Appalaches, Lévis, QC, Canada
- 700 1_
- $a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, AOU Policlinico Vittorio Emanuele, and Policlinico G. Rodolico, Catania, Italy
- 700 1_
- $a Csepany, Tunde $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Trabzon, Turkey
- 700 1_
- $a Lechner-Scott, Jeannette $u School of Medicine and Public Health, University Newcastle, and Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia
- 700 1_
- $a Granella, Franco $u Neurosciences Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy
- 700 1_
- $a Grand'Maison, Francois $u Neuro Rive-Sud, QC, Canada
- 700 1_
- $a van der Walt, Anneke $u Department of Neurology, Monash University, Melbourne, VIC, Australia
- 700 1_
- $a Zhu, Chao $u Department of Neurology, Monash University, Melbourne, VIC, Australia
- 700 1_
- $a Butzkueven, Helmut $u Central Clinical School and Department of Neurology, Monash University, and Department of Neurology, Alfred Hospital, Melbourne, VIC, Australia
- 710 2_
- $a MSBase Study Group
- 773 0_
- $w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 70, č. - (2023), s. 104477
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36746088 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141244 $b ABA008
- 999 __
- $a ok $b bmc $g 1924762 $s 1190493
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 70 $c - $d 104477 $e 20221223 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
- LZP __
- $a Pubmed-20230418
